PD-L1 expression as a predictive biomarker in cancer immunotherapy

Patel, Sandip Pravin, Kurzrock, Razelle·2015·Molecular Cancer Therapeutics

DOI 10.1158/1535-7163.mct-14-0983

Cited by (1,001)

Items 501–600 of 1,001

Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
Sergio Ayala‐Mar, Javier Donoso‐Quezada, José González‐Valdez · 2021 · Journal of Immunology Research
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
Ray Sagawa, Seiji Sakata, Bo Gong, Yosuke Seto, Ai Takemoto, Satoshi Takagi, Hironori Ninomiya, Noriko Yanagitani, Masayuki Nakao, Mingyon Mun et al. · 2021 · JCI Insight
Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer
Yun Liang, Wenshan Wang, Xiaojun Zhu, Minghua Yu, Caiyun Zhou · 2022 · Scientific Reports
Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer
Jiajia Zhang, Christopher Lee Wolfgang, Lei Zheng · 2018 · Cancers
From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma
Syed A. Hussain, Alison Jane Birtle, Simon J. Crabb, Robert Anthony Huddart, Diane Small, Maxwell Summerhayes, Robert J. Jones, Andrew S. Protheroe · 2018 · European Urology Oncology
The immune microenvironment and expression of PD‐L1, PD‐1, PRAME and MHC I in salivary duct carcinoma
Bin Xu, Achim A. Jungbluth, Denise Frosina, Bayan Alzumaili, Nathaniel Aleynick, Elzbieta A. Slodkowska, Kevin McLughlin Higgins, Alan Loh Ho, Luc G.T. Morris, Ronald A. Ghossein et al. · 2019 · Histopathology
Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis
Yin He, Xiaosheng Wang · 2020 · Annals of Translational Medicine
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
Corinne Faivre Finn, David Robert Spigel, Suresh Senan, Corey Jay Langer, Bradford A. Perez, Mustafa Özgüroğlu, Davey B. Daniel, Augusto E. Villegas, David Vicente, Rina Hui et al. · 2020 · Lung Cancer
Current Trends in Cancer Immunotherapy
Ivan Yurevich Filin, Valeriya V. Solovyeva, Kristina Viktorovna Kitaeva, Catrin Sian Rutland, Albert Anatolyevich Rizvanov · 2020 · Biomedicines
STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications
Nithya Krishnamurthy, Aaron Michael Goodman, Donald A. Barkauskas, Razelle Kurzrock · 2021 · European Journal of Cancer
Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer
Guoqiang Zhang, Qiong Jiao, Chen‐Tian Shen, Hong‐Jun Song, Huizhen Zhang, Zhong‐Ling Qiu, Quan‐Yong Luo · 2020 · Cancer Science
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
Yaolin Xu, Lijie He, Qiang Fu, Junzhe Hu · 2021 · Frontiers in Oncology
Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
Rongjuan Wang, Chang Zhang, Yuting Cao, Junchao Wang, Shasha Jiao, Jiao Zhang, Min Wang, Peipei Tang, Zijun Ouyang, Wenlu Liang et al. · 2022 · Theranostics
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Kexun Zhou, Shuo Li, Yi Zhao, Ke Cheng · 2023 · Frontiers in Immunology
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Jan‐Malte Placke, Mona Kimmig, Klaus Griewank, Rudolf Alexander Herbst, Patrick Andres Maximilian Terheyden, Jochen Sven Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Peter Mohr et al. · 2023 · EBioMedicine
Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses
Yijun Dong, Zongliang Zhang, Siyuan Luan, Meijun Zheng, Zeng Wang, Yongdong Chen, Xiaoting Chen, Aiping Tong, Hui Yang · 2024 · Journal for ImmunoTherapy of Cancer
Imaging Biomarkers in Immunotherapy
Rosalyn Anne Juergens, Katherine Zukotynski, Amit Singnurkar, Denis P. Snider, John F. Valliant, Karen Y. Gulenchyn · 2016 · Biomarkers in Cancer
Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma
Pooja Ghatalia, Matthew R. Zibelman, Daniel M. Geynisman, Elizabeth R. Plimack · 2017 · Current Treatment Options in Oncology
PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma
Edward Roper, Trina Lum, Carsten Erich Palme, Bruce Ashford, Sydney Ch’ng, Marie Ranson, Michael Joseph Boyer, Jonathan Robert Clark, Ruta Gupta · 2017 · Pathology
PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases
Irene García‐Díez, Eugenia Hernández-Ruiz, Evelyn Andrades, Javier Gimeno, Carla Ferrándiz‐Pulido, Mireia Yébenes, Vicente García‐Patos, Ramon Maria Pujol, Inmaculada Hernández‐Muñoz, Agustí Toll · 2018 · American Journal of Dermatopathology
Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
Tudor Mocan, Zeno Adrian Sparchez, Rareș Crăciun, Nelida Bora, Daniel‐Corneliu Leucuta · 2018 · Clinical & Translational Oncology
Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine
Hyunjoon Kim, Thomas S. Griffith, Jayanth Panyam · 2019 · Journal of Pharmacology and Experimental Therapeutics
Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer
Lukas W. Pfannenstiel, Claudia Marcela Diaz-Montero, Ye F. Tian, Joseph Scharpf, Jennifer S. Ko, Brian Gastman · 2019 · Cancer Immunology Research
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Yumeng Wang, Guiling Li · 2019 · Frontiers of Medicine
Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug
Na Shen, Chenguang Yang, Xuefei Zhang, Zhaohui Tang, Xuesi Chen · 2021 · Acta Biomaterialia
Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping
Moritz Jesinghaus, Katja Steiger, Julia Slotta‐Huspenina, Enken Drecoll, Nicole Pfarr, Petra Meyer, Björn Konukiewitz, Marcus Bettstetter, Kathrin S. Wieczorek, Katja Ott et al. · 2017 · Oncotarget
Potent immunogenicity in BRCA 1 ‐mutated patients with high‐grade serous ovarian carcinoma
Ying Dai, Chengdu Sun, Yi Feng, Qingzhu Jia, Bo Zhu · 2018 · Journal of Cellular and Molecular Medicine
Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription
John Pang, Nam Nguyen, Jens Luebeck, Laurel Ball, Andrey Finegersh, Shuling Ren, Takuya Nakagawa, Mitchell Flagg, Sayed Sadat, Paul S. Mischel et al. · 2021 · Clinical Cancer Research
Comparative molecular profiling of HPV‐induced squamous cell carcinomas
Robert F. Koncar, Rebecca A. Feldman, El Mustapha Bahassi, Nooshin Hashemi Sadraei · 2017 · Cancer Medicine
Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction
Yang Yang, Ke Wang, Hao Chen, Zhiqiang Feng · 2020 · European Journal of Medicinal Chemistry
Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression
Kazuki Takada, Tatsuro Okamoto, Masaki Tominaga, Koji Teraishi, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Gouji Toyokawa, Fumihiro Shoji, Masaki Okamoto et al. · 2017 · PLoS ONE
Co‐delivery Nano System of MS‐275 and V‐9302 Induces Pyroptosis and Enhances Anti‐Tumor Immunity Against Uveal Melanoma
Hong Ren, Zhenkai Wu, Jia Tan, Hui Tao, Wangyuan Zou, Zheng Cao, Binyu Wen, Ziyi Cai, Jiaqi Du, Zhihong Deng · 2024 · Advanced Science
New therapeutic strategies for malignant pleural mesothelioma
Mara A. Bonelli, Claudia Fumarola, Silvia La Monica, Roberta R Alfieri · 2016 · Biochemical Pharmacology
A Preclinical Assessment of 89 Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89 Zr-C4
Anna Moroz, Chia-Yin Lee, Yung-Hua Wang, Jeffrey C. Hsiao, Natalia Sevillano, Charles Truillet, Charles S. Craik, Lawrence H. Fong, Cheng‐I Wang, Michael J. Evans · 2018 · Bioconjugate Chemistry
Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers
Shu‐Fen Chiang, Kevin Chih‐Yang Huang, Tao‐Wei Ke, Tsung-Wei Chen, Yu-Ching Lan, Ying‐Shu You, William Tzu‐Liang Chen, K. S. Clifford Chao · 2018 · Cancer Immunology Immunotherapy
Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
Shuji Mikami, Ryuichi Mizuno, Tsunenori Kondo, Nobuo Shinohara, Norio Nonomura, Seiichiro Ozono, Masatoshi Eto, Katsunori Tatsugami, Tatsuya Takayama, Hideyasu Matsuyama et al. · 2019 · Cancer Science
Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma
Shamik Mitra, Martin Lauss, Rita Cabrita, Jiyeon Choi, Tongwu Zhang, Karolin Isaksson, Hakan Lars Olsson, Christian Ingvar, Ana Carneiro, Johan Staaf et al. · 2020 · Molecular Oncology
Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade
Christina Jensen, Dovilė Sinkevičiūtė, Daniel Hargbøll Madsen, Patrik Önnerfjord, Morten Hansen, Henrik Schmidt, M.A. Karsdal, Inge Marie Svane, Nicholas Willumsen · 2020 · Cancers
Subgroup-Independent Mapping of Renal Cell Carcinoma—Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries
André Marquardt, Antonio Giovanni Solimando, Alexander Kerscher, Max Bittrich, Charis Kalogirou, Hubert R Kübler, Andreas Rosenwald, Ralf Christian Bargou, Philip Kollmannsberger, Bastian Schilling et al. · 2021 · Frontiers in Oncology
Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
Amit Mahipal, Sri Harsha Tella, Anuhya Kommalapati, Alexander Lim, Richard D. Kim · 2019 · Cancers
Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors
Kuan Hu, Wenyu Wu, Lin Xie, Hao Ran Geng, Yiding Zhang, Masayuki Hanyu, Lulu Zhang, Yinghuan Liu, Kotaro Nagatsu, Hisashi Suzuki et al. · 2021 · Acta Pharmaceutica Sinica B
Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data
Mengyuan Li, Xuejiao Gao, Xiaosheng Wang · 2023 · Frontiers in Immunology
MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response
Bin Zhang, Chun‐Mei Wang, Hao‐Xiang Wu, Feng Wang, Yangyang Chai, Ye Hu, Bingjing Wang, Yu Ling Zhou, Rong‐Hua Xia, Rui‐Hua Xu et al. · 2023 · 癌症：英文版
Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways
Songyu Shen, Yihan Hong, Jiajun Huang, Xiaosheng Qu, Suren Rao Sooranna, Sheng Lu, Tian Xiang Li, Bing Niu · 2024 · Cytokine & Growth Factor Reviews
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer
Jordi Remón, Nathalie Chaput, David Planchard · 2016 · Current Opinion in Oncology
Systems immune monitoring in cancer therapy
Allison R. Greenplate, Douglas Buckner Johnson, Paul Brent Ferrell, Jonathan Michael Irish · 2016 · European Journal of Cancer
An aptamer for recognizing the transmembrane protein PDL-1 (programmed death-ligand 1), and its application to fluorometric single cell detection of human ovarian carcinoma cells
Rezvan Yazdian Robati, Mohammad Ramezani, Mostafa Khedri, Najmeh Ansari, Khalil Abnous, Seyed Mohammad Taghdisi · 2017 · Microchimica Acta
Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms
Christina Koppel, Helena Schwellenbach, Dirk Zielinski, Sina Eckstein, Mercedes Martin-Ortega, Corrado D’Arrigo, Hans‐Ulrich Schildhaus, Josef Rüschoff, Bharat Jasani · 2018 · Modern Pathology
PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications
Salvatore Ulisse, Chiara Tuccilli, Salvatore Sorrenti, Alessandro Antonelli, Poupak Fallahi, Eleonora D’Armiento, A Catania, Francesco Tartaglia, Maria Ida Amabile, Laura Giacomelli et al. · 2019 · International Journal of Molecular Sciences
PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population
Lulu Rong, Yong Liu, Zhouguang Hui, Zitong Zhao, Yueming Zhang, Bingzhi Wang, Yanling Yuan, Wenbin Li, Lei Guo, Jianming Ying et al. · 2019 · Diagnostic Pathology
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
Jialin Qu, Man Jiang, Li Wang, Deze Zhao, Kang Qin, Yun Wang, Junyan Tao, Xiaochun Zhang · 2020 · Biomedicine & Pharmacotherapy
A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
Jialin Qu, Li Wang, Man Jiang, Deze Zhao, Yuyang Wang, Feng Zhang, Jing Li, Xiaochun Zhang · 2020 · Cancer Management and Research
Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
Harm Westdorp, Mark W. D. Sweep, Mark A.J. Gorris, Frank Hoentjen, Marye J. Boers‐Sonderen, Rachel S. van der Post, Michel M. van den Heuvel, Berber Piet, Annemarie Boleij, Haiko J. Bloemendal et al. · 2021 · Frontiers in Immunology
Profiling of immune features to predict immunotherapy efficacy
Youqiong Ye, Yongchang Zhang, Nong Yang, Qian Gao, Xinyu Ding, Xinwei Kuang, Rujuan Bao, Zhao Zhang, Chaoyang Sun, Bingying Zhou et al. · 2021 · The Innovation
Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy
Eric K. Ring, James M. Markert, G. Yancey Gillespie, Gregory K. Friedman · 2016 · Clinical Cancer Research
Epithelial-to-Mesenchymal Transition in the Pathogenesis and Therapy of Head and Neck Cancer
Julia Thierauf, Johannes A. Veit, Jochen Heß · 2017 · Cancers
Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
Shumei Kato, Kellie Kurasaki, Sadakatsu Ikeda, Razelle Kurzrock · 2017 · The Oncologist
Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma
Stefanie Fischer, Omar Hasan Ali, Wolfram Jochum, Thomas Kluckert, Lukas Flatz, Marco Siano · 2018 · Oncology Research and Treatment
Clinical relevance of PD ‐L1 expression in gallbladder cancer: a potential target for therapy
Azfar Neyaz, Nuzhat Husain, Swati Kumari, Sameer Gupta, Saumya Shukla, Sanya Arshad, Nidhi Anand, Arun Chaturvedi · 2018 · Histopathology
Immune therapy of melanoma: Overview of therapeutic vaccines
Zahra Payandeh, Maral Yarahmadi, Ziba Nariman‐Saleh‐Fam, Vahideh Tarhriz, Maryam Islami, Abdolreza Mehdinavaz Aghdam, Shirin Eyvazi · 2019 · Journal of Cellular Physiology
The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer
Lin Zhang, Xiaohong Iris Wang, Jianmin Ding, Qigang Sun, Songlin Zhang · 2019 · Annals of Diagnostic Pathology
Porphyromonas gingivalis Cell Wall Components Induce Programmed Death Ligand 1 (PD-L1) Expression on Human Oral Carcinoma Cells by a Receptor-Interacting Protein Kinase 2 (RIP2)-Dependent Mechanism
Sabine Elisabeth. Groeger, Fabian Denter, Günter Lochnit, Michael Lienhard Schmitz, Joerg Meyle · 2020 · Infection and Immunity
New electrochemical method for programmed death-ligand 1 detection based on a paper-based microfluidic aptasensor
Yu Xing, Juntao Liu, Shuai Sun, Ming Tao, Yang Wang, Jinping Luo, Guihua Xiao, Xinrong Li, Jingyu Xie, Xinxia Cai · 2021 · Bioelectrochemistry
The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial
Rui Li, Yuncong Liu, Rutie Yin, Limei Yin, Kemin Li, Chuntang Sun, Zhipeng Zhou, Pansong Li, Ruizhan Tong, Jianxin Xue et al. · 2021 · International Journal of Radiation Oncology*Biology*Physics
A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle
Zhenhan Feng, Zhan-Tao Li, Shuang Zhang, Jingru Wang, Zhuoyue Li, Mei-Qi Xu, Hui Li, Shuaiqiang Zhang, Guang-xue Wang, Ai Liao et al. · 2021 · Acta Biomaterialia
A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study
Kexue Deng, Lu Wang, Yuchan Liu, Xin Li, Qiuyang Hou, Mulan Cao, Nathan Norton Ng, Huan Wang, Huanhuan Chen, Kristen W. Yeom et al. · 2022 · EClinicalMedicine
Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer
Peng‐Peng Kuang, Ning Li, Zui Liu, Tianyu Sun, Shu-Quan Wang, Jia Hu, Wei Ou, Si-Yu Wang · 2021 · Frontiers in Oncology
Immunotherapy for Gastric Cancer: A 2021 Update
Christo Kole, Nikolaos Charalampakis, Sergios A. Tsakatikas, Nikolaos-Iasonas Kouris, George Papaxoinis, Michalis V. Karamouzis, Anna A. Koumarianou, Dimitriοs Schizas · 2021 · Immunotherapy
eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma
Xisha Chen, Kuansong Wang, Shilong Jiang, Hongyin Sun, 车炫霖, Minghui Zhang, Jiaying He, Ying Wen, Mengting Liao, Xiangling Li et al. · 2022 · Journal for ImmunoTherapy of Cancer
Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer
Lisha Wang, Zebing Liu, Kurt W. Fisher, Fei Ren, Jiaojie Lv, Darrell D. Davidson, Lee Ann Baldridge, Xiang Du, Liang Cheng C · 2017 · Human Pathology
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
Jun Ishihara, Ako Ishihara, Lambert Potin, Peyman Hosseinchi, Kazuto Fukunaga, Martina Damo, Thomas Frank Gajewski, Melody A. Swartz, Jeffrey A. Hubbell · 2018 · Molecular Cancer Therapeutics
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
Hong Sook Kim, Hongui Cha, Jin-Ho Kim, Woong‐Yang Park, Yoon‐La Choi, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Se‐Hoon Lee · 2019 · European Journal of Cancer
Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry
Landon J. Inge, Eslie Dennis · 2020 · Immuno-Oncology Technology
Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
Zhu Zeng, Biao Yang, Zhengyin Liao · 2021 · Frontiers in Oncology
FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma
Yilin Yu, Zhiping Wang, Qunhao Zheng, Jiancheng Li · 2021 · Aging
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Elena Fountzilas, Razelle Kurzrock, Henry Hiep Vo, Apostolia Maria Tsimberidou · 2021 · JNCI Journal of the National Cancer Institute
To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3
Ranjana Kumari Kanchan, David Doss, Parvez Κhan, Mohd Wasim Nasser, Sidharth Mahapatra · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy
Xiangyu Yin, Xue Song, Wanglong Deng, NEIL W. BLAKE, Xinghong Luo, Jia Meng · 2024 · Frontiers in Oncology
Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer
Lisha Wang, Fei Ren, Qifeng Wang, Lee Ann Baldridge, Maria Francesca Monn, Kurt W. Fisher, Weiqi Sheng, Xiaoyan Zhou, Xiang Du, Liang Cheng C · 2016 · Molecular Diagnosis & Therapy
Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients
Atsushi Mitsuhashi, Yusuke Okuma · 2018 · Clinical & Translational Oncology
Multi‐omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma
Chuanjie Zhang, Luping Shen, Feng Qi, Jincheng Wang, Jun Luo · 2019 · Journal of Cellular Physiology
Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E/K mutated malignant melanomas
Sebastian Klein, Cornelia Mauch, Klaus Brinker, Ka‐Won Noh, Sonja Knez, Reinhard Büttner, Alexander Quaas, Doris Helbig · 2021 · Scientific Reports
Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma
E. Chasseuil, Mélanie Saint-Jean, H. Chasseuil, L. Peuvrel, Gaelle Quereux, Jean‐Michel Nguyen, Aurélie Gaultier, Émilie Varey, Amir Khammari, Brigitte Dréno · 2018 · Acta Dermato Venereologica
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing
Benjamin E. Paluch, Sean T. Glenn, Jeffrey M. Conroy, Antonios Papanicolau‐Sengos, Wiam Bshara, Angela R. Omilian, Elizabeth Brese, Mary Nesline, Blake Burgher, Jonathan Andreas et al. · 2016 · Oncotarget
Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma
Xiao Hua SHI, Pengcheng Yu, Bowen Lei, Cui-Wei Li, Yan Zhang, Li-Cheng Tan, Rong‐Liang Shi, Jie Wang, Ben Ma, Weibo Xu et al. · 2019 · Thyroid
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
Magdalena Olbryt, Marcin Rajczykowski, Wiesława Widłak · 2020 · International Journal of Molecular Sciences
Preclinical PET imaging with the novel human antibody 89 Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues
Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Tomas C. Arnold, Jason T. Giurleo, Richard Tavaré, Makenzie A. Danton, Christian Granados, Ishita Chatterjee, Drew Dudgeon et al. · 2021 · Journal for ImmunoTherapy of Cancer
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
Xi Chen, Liangjie Fang, Yan‐Ping Zhu, Zhang Bao, Qing Wang, Rong Liu, Wenjia Sun, Haiwei Du, Jing Lin, Bing Yu et al. · 2021 · Cancer Immunology Immunotherapy
PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer
Fei Wu, Yanzi Gu, Bin Kang, Fabienne Heskia, Alexandre Pachot, Marc Bonneville, Ping Wei, Ji Liang · 2021 · Translational Lung Cancer Research
Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy
Adelaide Alves, Margarida Dias, Sérgio Campainha, Ana Barroso · 2021 · Journal of Thoracic Disease
Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
Miaomiao Gou, Niansong Qian, Yong Zhang, Huan Yan, Haiyan Si, Zhikuan Wang, Guanghai Dai · 2022 · Frontiers in Oncology
Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects
Dimitrios I. Bafaloukos, Ioanna Gazouli, Christos Koutserimpas, George Samonis · 2023 · Vaccines
PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled αPD-L1 antibody
Jingyun Ren, Mengxin Xu, Junyi Chen, Jie Ding, Peipei Wang, Li Huo, Fang Li, Zhibo Liu · 2020 · Theranostics
CTLA-4 Expression and Its Clinical Significance in Breast Cancer
Rodrigo Kern, Carolina Panis · 2021 · Archivum Immunologiae et Therapiae Experimentalis
A tumor vasculature–based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors
Mehdi Alilou, Mohammadhadi Khorrami, Prateek Prasanna, Kaustav Bera, Amit Banwari Gupta, Vidya Sankar Viswanathan, Pradnya Dinkar Patil, Priya Velu, Pingfu Fu, Vamsidhar Velcheti et al. · 2022 · Science Advances
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520
Soham D. Puvvada, Hongli Li, Lisa M. Rimsza, Steven H. Bernstein, Richard I. Fisher, Michael Leo LeBlanc, Monika Schmelz, Betty Glinsmann‐Gibson, Thomas P. Miller, Anne‐Marie Maddox et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
Shuhang Wang, Miaomiao Jiang, Zuozhen Yang, Xiaoyun Huang, Ning Li · 2020 · Genes & Diseases
Stromal score as a prognostic factor in primary gastric cancer and close association with tumor immune microenvironment
Min Mao, Qingliang Yu, Rongzhi Huang, Yun‐Xin Lu, Zhen Wang, Liang Liao · 2020 · Cancer Medicine
Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy
Shumin Yuan, Yuqing Liu, Brian G. Till, Yongping Song, Zibing Wang · 2020 · Frontiers in Immunology
Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease
Stella Meireles Siqueira, Gabriella Campos‐do‐Carmo, Alexssandra Lima Siqueira dos Santos, Cicero Luiz Cunha De Sousa Martins, Andréia Cristina de Melo · 2023 · Anais Brasileiros de Dermatologia